ArticleBMC cancer2025
A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LDCT screening for lung cancer in East Asian never-smokers: balancing benefits and overdiagnosis-related harms.The Lancet regional health. Western Pacific · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundWell-implemented cancer screening strategies can significantly enhance early detection rates, leading to improved treatment outcomes and reduced mortality. However, there remains a paucity of high-quality evidence from developing regions. The CHinA National CancEr Screening (CHANCES) Trial aims to comprehensively evaluate and compare different screening strategies for lung cancer and colorectal cancer (CRC) in the Chinese population.
methodsThe CHANCES trial is a randomized controlled trial aimed at assessing the effectiveness of screening using low-dose computed tomography (LDCT) either annually or biennially for reducing lung cancer-specific mortality. Additionally, our trial seeks to evaluate the efficacy of various screening strategies for CRC. In this 5-year project, a total of 105,600 participants aged 50-74 from 25 provinces will be enrolled and randomized into one of three arms: (i) receiving five annual LDCT scans along with a single colonoscopy (n = 26,400); (ii) undergoing three biennial LDCT scans and five annual fecal blood tests using fecal immunochemical testing (FIT) (n = 39,600); (iii) opting for either a single colonoscopy or five annual FIT tests (n = 39,600). Participants with positive FIT findings will be recommended to undergo a diagnostic colonoscopy. The primary endpoint of this study is lung cancer-specific mortality, and cost-effectiveness analyses of the various screening strategies in the Chinese population are also planned. DISCUSSION: To our knowledge, this trial represents the first endeavor statistically powered to assess the potential reduction in lung-cancer-specific mortality through screening with LDCT annually or biennially compared to a no screening arm. Additionally, it seeks to explore the feasibility of integrating lung cancer and CRC screening in a developing nation setting. The anticipated findings from this study hold the potential to provide evidence-based recommendations for cancer screening programs, thereby advancing cancer prevention and control efforts not only in China but also globally.
trial registrationChiCTRN(Chinese Clinical Trial Registry Number), ChiCTR1900025257. Registered on 2019-08-18.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.